title: Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.
abstract: Doxycycline, a synthetically derived tetracycline, is a partially efficacious causal prophylactic (liver stage of Plasmodium) drug and a slow acting blood schizontocidal agent highly effective for the prevention of malaria. When used in conjunction with a fast acting schizontocidal agent, it is also highly effective for malaria treatment. Doxycycline is especially useful as a prophylaxis in areas with chloroquine and multidrug-resistant Plasmodium falciparum malaria. Although not recommended for pregnant women and children < 8 years of age, severe adverse events are rarely reported for doxycycline. This report examines the evidence behind current recommendations for the use of doxycycline for malaria and summarizes the available literature on its safety and tolerability.
authors: Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, 4770 Buford Hwy., Atlanta, GA 30341, USA. ktan@cdc.gov
authors: Kathrine R
authors: KR
authors: Tan
authors: Alan J
authors: AJ
authors: Magill
authors: Monica E
authors: ME
authors: Parise
authors: Paul M
authors: PM
authors: Arguin
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D004318:Doxycycline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D011247:Pregnancy; D014481:United States
chemical_list: D000962:Antimalarials; D004318:Doxycycline